BioCryst Pharmaceuticals has been granted a patent for compounds that inhibit viral RNA polymerase, potentially treating Zika virus infections. The patent covers methods of administering these compounds to treat or suppress Zika-related diseases in subjects. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of zika virus infection using compound of formula i
A recently granted patent (Publication Number: US11975003B2) discloses a method for treating or suppressing diseases or conditions associated with Zika virus infection in a subject. The method involves administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to the subject. The patent claims cover various aspects of the treatment method, including the administration of a single dose of the compound during a course of treatment, the option for multiple doses with varying amounts, and the use of different administration routes such as intravenous, intramuscular, parenteral, or oral.
Furthermore, the patent claims also encompass the administration of the compound of formula I as part of a pharmaceutical composition, which includes the compound and a pharmaceutically acceptable carrier. The method allows for flexibility in dosing regimens, including the option for loading doses and maintenance doses during the course of treatment. This patent provides a framework for effectively addressing diseases or conditions associated with Zika virus infection, offering potential treatment options for subjects in need of medical intervention.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
